Hepatitis C Virus (HCV): A Review of Immunological Aspects

REFERENCES

• Choo Q. L., Richman K. H., Han J. H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P. J., et al. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 1991; 88(6)2451–2455
   Google Scholar
• Flaviviridae: The viruses and their replication, B. D. Lindenbach, C. M. Rice. Lippincott Williams & Wikins, Philadelphia, PA 2001; 991–1041
   Google Scholar
• Voisset C., Dubuisson J. Functional hepatitis C virus envelope glycoproteins. Biol. Cell 2004; 96(6)413–420
   Google Scholar
• Wack A., Soldaini E., Tseng C., Nuti S., Klimpel G., Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur. J. Immunol. 2001; 31(1)166–175
   Google Scholar
• Tseng C. T., Klimpel G. R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 2002; 195(1)43–49
   PubMedGoogle Scholar
• Armstrong G. L., Wasley A., Simard E. P., McQuillan G. M., Kuhnert W. L., Alter M. J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 2006; 144(10)705–714
   PubMed Web of Science ®Google Scholar
• El-Serag H. B., Davila J. A., Petersen N. J., McGlynn K. A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann. Intern. Med. 2003; 139(10)817–823
   PubMed Web of Science ®Google Scholar
• Soriano V., Sulkowski M., Bergin C., Hatzakis A., Cacoub P., Katlama C., Cargnel A., Mauss S., Dieterich D., Moreno S., Ferrari C., Poynard T., Rockstroh J. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813–828
   PubMed Web of Science ®Google Scholar
• Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A. J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998; 282: 938–941
   PubMed Web of Science ®Google Scholar
• Masciopinto F., Freer G., Burgio V. L., Levy S., Galli-Stampino L., Bendinelli M., Houghton M., Abrignani S., Uematsu Y. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 2002; 304: 187–196
   PubMedGoogle Scholar
• Maecker H. T., Todd S. C., Levy S. The tetraspanin superfamily: Molecular facilitators. FASEB J. 1997; 11: 428–442
   PubMed Web of Science ®Google Scholar
• Flint M., Maidens C., Loomis-Price L. D., Shotton C., Dubuisson J., Monk P., Higginbottom A., Levy S., McKeating J. A. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 1999; 73: 6235–6244
   PubMed Web of Science ®Google Scholar
• Lozach P. Y., Lortat-Jacob H., De Lacroix D. L., Staropoli I., Foung S., Amara A., Houles C., Fieschi F., Schwartz O., Virelizier J. L., Arenzana-Seisdedos F., Altmeyer R. DC-SIGN and L-SIGN are high-affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 2003; 278: 20358–20366
   PubMed Web of Science ®Google Scholar
• Scarselli E., Ansuini H., Cerino R., Roccasecca R. M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo J. 2002; 21: 5017–5025
   PubMed Web of Science ®Google Scholar
• Roccasecca R., Ansuini H., Vitelli A., Meola A., Scarselli E., Acali S., Pezzanera M., Ercole B. B., McKeating J., Yagnik A., Lahm A., Tramontano A., Cortese R., Nicosia A. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain-specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J. Virol. 2003; 77: 1856–1867
   Web of Science ®Google Scholar
• Frasca L., Del Porto P., Tuosto L., Marinari B., Scotta C., Carbonari M., Nicosia A., Piccolella E. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. J. Immunol. 1999; 163: 650–658
   PubMed Web of Science ®Google Scholar
• Kim H. S., Lee J. K., Yang I. H., Ahn J. K., Oh Y. I., Kim C. J., Kim Y. S., Lee C. K. Identification of hepatitis C virus core domain inducing suppression of allostimulatory capacity of dendritic cells. Arch. Pharm. Res. 2002; 25(3)364–369
   Google Scholar
• Sarobe P., Lasarte J. J., Zabaleta A., Arribillaga L., Arina A., Melero I., Borrás-Cuesta F., Prieto J. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J. Virol. 2003; 77(20)10862–10871
   Google Scholar
• Kanto T., Inoue M., Miyatake H., Sato A., Sakakibara M., Yakushijin T., Oki C., Itose I., Hiramatsu N., Takehara T., Kasahara A., Hayashi N. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J. Infect. Dis. 2004; 190(11)1919–1926
   PubMed Web of Science ®Google Scholar
• Murakami H., Akbar S. M., Matsui H., Horiike N., Onji M. Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin. Exp. Immunol. 2003; 137(3)559–565
   Google Scholar
• Ulsenheimer A., Gerlach J. T., Gruener N. H., Jung M. C., Schirren C. A., Schraut W., Zachoval R., Pape G. R., Diepolder H. M. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003; 37(5)1189–1198
   PubMed Web of Science ®Google Scholar
• Rosa D., Saletti G., De Gregorio E., Zorat F., Comar C., D'Oro U., Nuti S., Houghton M., Barnaba V., Pozzato G., Abrignani S. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102(51)18544–18549
   PubMed Web of Science ®Google Scholar
• Zhao L. J., Wang L., Ren H., Cao J., Li L., Ke J. S., Qi Z. T. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptor. Exp. Cell Res. 2005; 305(1)23–32
   PubMed Web of Science ®Google Scholar
• Mazzocca A., Sciammetta S. C., Carloni V., et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic. J. Biol. Chem. 2005; 280: 11329–11339
   PubMed Web of Science ®Google Scholar
• Gerlach J. T., Diepolder H. M., Jung M. C., Gruener N. H., Schraut W. W., Zachoval R., Hoffmann R., Schirren C. A., Santantonio T., Pape G. R. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117(4)933–941
   Web of Science ®Google Scholar
• Chan S. H., Perussia B., Gupta J. W., Kobayashi M., Pospísil M., Young H. A., Wolf S. F., Young D., Clark S. C., Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J. Exp. Med. 1991; 173(4)869–879
   PubMed Web of Science ®Google Scholar
• Heufler C., Koch F., Stanzl U., Topar G., Wysocka M., Trinchieri G., Enk A., Steinman R. M., Romani N., Schuler G. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur. J. Immunol. 1996; 26(3)659–668
   PubMed Web of Science ®Google Scholar
• Pape G. R., Gerlach T. J., Diepolder H. M., Grüner N., Jung M., Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J. Viral Hepat. 1999; 6(Suppl 1)36–40
   Google Scholar
• Aberle J. H., Formann E., Steindl-Munda P., Weseslindtner L., Gurguta C., Perstinger G., Grilnberger E., Laferl H., Dienes H. P., Popow-Kraupp T., Ferenci P., Holzmann H. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J. Clin. Virol. 2006; 36(1)24–31
   Google Scholar
• Banchereau J., Steinman R. M. Dendritic cells and the control of immunity. Nature 1998; 392(6673)245–252
   PubMed Web of Science ®Google Scholar
• Lauer G. M., Walker B. D. Hepatitis C virus infection. N. Engl. J. Med. 2001; 345: 41–52
   PubMed Web of Science ®Google Scholar
• Valiante N. M., D'Andrea A., Crotta S., Lechner F., Klenerman P., Nuti S., Wack A., Abrignani S. Life, activation, and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol. Rev. 2000; 174: 77–89
   Google Scholar
• Su A. I., Pezacki J. P., Wodicka L., Brideau A. D., Supekova L., Thimme R., Wieland S., Bukh J., Purcell R. H., Schultz P. G., Chisari F. V. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2002; 99: 15669–15674
   PubMed Web of Science ®Google Scholar
• Koziel M. J. The role of immune responses in the pathogenesis of hepatitis C virus infection. J. Viral Hepat. 1997; 4(Suppl. 2)31–41
   Google Scholar
• Chisari F. V. Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 1997; 99: 1472–1477
   PubMed Web of Science ®Google Scholar
• Cooper S., Erickson A. L., Adams E. J., Kansopon J., Weiner A. J., Chien D. Y., Houghton M., Parham P., Walker C. M. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439–449
   PubMed Web of Science ®Google Scholar
• Shata M. T., Anthony D. D., Carlson N. L., Andrus L., Brotman B., Tricoche N., McCormack P., Prince A. Characterization of the immune response against hepatitis C infection in recovered and chronically infected chimpanzees. J. Viral Hepat. 2002; 9: 400–410
   PubMed Web of Science ®Google Scholar
• Thimme R., Bukh J., Spangenberg H. C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R. H., Chisari F. V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 2002; 99: 15661–15668
   PubMed Web of Science ®Google Scholar
• Bowen D. G., Walker C. M. The origin of quasispecies: Cause or consequence of chronic hepatitis C viral infection?. J. Hepatol. 2005; 42(3)408–417
   PubMed Web of Science ®Google Scholar
• Weiner A. J., Brauer M. J., Rosenblatt J., Richman K. H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q. L., Houghton M., et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180(2)842–848
   Google Scholar
• Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J. C., Strazzera A., Chien D. Y., Munoz S. J., Balestrieri A., Purcell R. H., Alter H. J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288(5464)339–344
   PubMed Web of Science ®Google Scholar
• Farci P., Alter H. J., Wong D. C., Miller R. H., Govindarajan S., Engle R., Shapiro M., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 1994; 91(16)7792–7796
   PubMed Web of Science ®Google Scholar
• Shimizu Y. K., Hijikata M., Iwamoto A., Alter H. J., Purcell R. H., Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 1994; 68: 1494–1500
   PubMed Web of Science ®Google Scholar
• Del Porto P., Puntoriero G., Scottà C., Nicosia A., Piccolella E. High prevalence of hypervariable region 1-specific and -cross-reactive CD4(+) T cells in HCV-infected individuals responsive to IFN-alpha treatment. Virology 2000; 269(2)313–324
   Google Scholar
• Tsai S. L., Chen Y. M., Chen M. H., Huang C. Y., Sheen I. S., Yeh C. T., Huang J. H., Kuo G. C., Liaw Y. F. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998; 115(4)954–965
   Google Scholar
• Frasca L., Scottà C., Del Porto P., Nicosia A., Pasquazzi C., Versace I., Masci A. M., Racioppi L., Piccolella E. Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. Hepatology 2003; 38(3)653–663
   Google Scholar
• Grakoui A., Shoukry N. H., Woollard D. J., Han J. H., Hanson H. L., Ghrayeb J., Murthy K. K., Rice C. M., Walker C. M. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302(5645)659–662
   PubMed Web of Science ®Google Scholar
• Manzin A., Solforosi L., Petrelli E., Macarri G., Tosone G., Piazza M., Clementi M. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J. Virol. 1998; 72(7)6271–6276
   Google Scholar
• Ray S. C., Wang Y. M., Laeyendecker O., Ticehurst J. R., Villano S. A., Thomas D. L. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy. J. Virol. 1999; 73(4)2938–2946
   Google Scholar
• Dustin L. B., Rice C. M. Flying under the radar: The immunobiology of hepatitis C. Annu. Rev. Immunol. 2007; 25: 71–99
   PubMed Web of Science ®Google Scholar
• Shoukry N. H., Cawthon A. G., Walker C. M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu. Rev. Microbiol. 2004; 58: 391–424
   Google Scholar
• Bowen D. G., Walker C. M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946–952
   PubMed Web of Science ®Google Scholar
• Thimme R., Lohmann V., Weber F. A target on the move: Innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 2006; 69: 129–141
   PubMed Web of Science ®Google Scholar
• Boettler T., Spangenberg H. C., Neumann-Haefelin C., Panther E., Urbani S., Ferrari C., Blum H. E., von Weizsacker F., Thimme R. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J. Virol. 2005; 79: 7860–7867
   PubMed Web of Science ®Google Scholar
• Cabrera R., Tu Z., Xu Y., Firpi R. J., Rosen H. R., Liu C., Nelson D. R. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062–1071
   PubMed Web of Science ®Google Scholar
• Sugimoto K., Ikeda F., Stadanlick J., Nunes F. A., Alter H. J., Chang K. M. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38: 1437–1448
   PubMed Web of Science ®Google Scholar
• Rushbrook S. M., Ward S. M., Unitt E., Vowler S. L., Lucas M., Klenerman P., Alexander G. J. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J. Virol. 2005; 79: 7852–7859
   PubMed Web of Science ®Google Scholar
• Ward S. M., Fox B. C., Brown P. J., Worthington J., Fox S. B., Chapman R. W., Fleming K. A., Banham A. H., Klenerman P. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J. Hepatol. 2007; 47: 316–324
   PubMed Web of Science ®Google Scholar
• Bolacchi F., Sinistro A., Ciaprini C., Demin F., Capozzi M., Carducci F. C., Drapeau C. M., Rocchi G., Bergamini A. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin. Exp. Immunol. 2006; 144: 188–196
   PubMed Web of Science ®Google Scholar
• Manigold T., Shin E. C., Mizukoshi E., Mihalik K., Murthy K. K., Rice C. M., Piccirillo C. A., Rehermann B. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 2006; 107: 4424–4432
   PubMed Web of Science ®Google Scholar
• MacDonald A. J., Duffy M., Brady M. T., McKiernan S., Hall W., Hegarty J., Curry M., Mills K. H. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J. Infect. Dis. 2002; 185: 720–727
   PubMed Web of Science ®Google Scholar
• Accapezzato D., Francavilla V., Paroli M., Casciaro M., Chircu L. V., Cividini A., Abrignani S., Mondelli M. U., Barnaba V. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J. Clin. Invest. 2003; 113: 963–972
   Google Scholar
• Abel M., Sene D., Pol S., Bourliere M., Poynard T., Charlotte F., Cacoub P., Caillat-Zucman S. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 2006; 44: 1607–1616
   PubMed Web of Science ®Google Scholar
• Alatrakchi N., Graham C. S., van der Vliet H. J., Sherman K. E., Exley M. A., Koziel M. J. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J. Virol. 2007; 81: 5882–5892
   PubMed Web of Science ®Google Scholar
• Kammer A. R., van der Burg S. H., Grabscheid B., Hunziker I. P., Kwappenberg K. M., Reichen J., Melief C. J., Cerny A. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J. Exp. Med. 1999; 190: 169–176
   PubMed Web of Science ®Google Scholar
• Chan C. H., Hadlock K. G., Foung S. K., Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2002; 97: 1023–1026
   Google Scholar
• Agnello V., Chung R. T., Kaplan L. M. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 1992; 327: 1490–1495
   PubMed Web of Science ®Google Scholar
• Ivanovski M., Silvestri F., Pozzato G., Anand S., Mazzaro C., Burrone O. R., Efremov D. G. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91: 2433–2442
   PubMed Web of Science ®Google Scholar
• Ndimbie O. K., Nedjar S., Kingsley L., Riddle P., Rinaldo C. Long-term serologic follow-up of hepatitis C virus-seropositive homosexual men. Clin. Diagn. Lab. Immunol. 1995; 2: 219–224
   Google Scholar
• Farci P., Alter H. J., Govindarajan S., Wong D. C., Engle R., Lesniewski R. R., Mushahwar I. K., Desai S. M., Miller R. H., Ogata N. R., Purcell R. H. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135–144
   PubMed Web of Science ®Google Scholar
• Yuki N., Hayashi N., Ohkawa K., Hagiwara H., Oshita M., Katayama K., Sasaki Y., Kasahara A. A., Fusamoto H., Kamata T. The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C. Hepatology 1995; 22: 402–406
   Google Scholar
• Kato N., Yokosuka O., Hosoda K., Ito Y., Ohto M., Omta M. Detection of hepatitis C virus RNA in acute non-A, non-B hepatitis as an early diagnostic tool. Biochem. Biophys. Res. Commun. 1993; 192: 800–807
   PubMedGoogle Scholar
• Kao J. H., Chen P. J., Lai M. Y., Chen D. S. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology 1993; 105: 583–587
   Google Scholar
• Lai M. E., Mazzoleni A. P., Argiolu F., Devirgillis S., Balestrieri A., Purcell R. H., Cao A., Farci P. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388–390
   PubMed Web of Science ®Google Scholar
• Bradley D. W., Krawczynski K., Ebert J. W., McCaustland K. A., Choo Q. L., Houghton M., Kuo G. Parentally transmitted non-A, non-B hepatitis: Virus-specific antibody response patterns in hepatitis C virus-infected chimpanzees. Gastroenterology 1990; 99: 1054–1060
   PubMed Web of Science ®Google Scholar
• Alter H. J., Purcell R. H., Shih J. W., Melpolder J. C., Houghton M., Choo Q. L., Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 1989; 321: 1494–1500
   PubMed Web of Science ®Google Scholar
• Chien D. Y., Choo Q. L., Ralston R., Spaete R., Tong M., Houghton M. Persistence of HCV despite antibodies to both putative envelope glyproteins. Lancet 1993; 342: 933–935
   PubMed Web of Science ®Google Scholar
• Chemello L., Cavalletto D., Pontisso P., Bortocotti F., Donada C., Donadon V., Frezza M., Casazin P., Alberti A. Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. Hepatology 1993; 17: 179–182
   PubMed Web of Science ®Google Scholar
• Rodriguez-Luna H., Khatib A., Sharma P., De Petris G., Williams J. W., Ortiz J., Hansen K., Mulligan D., Moss A., Douglas D. D., Balan V., Rakela J., Vargas H. E. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α 2b and ribavirin: An open-label series. Transplantation 2004; 77: 190–194
   PubMed Web of Science ®Google Scholar
• Choueiri T. K., Hutson T. E., Bukowski R. M. Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 2003; 3: 823–829
   PubMedGoogle Scholar
• Stone S. F., Lee S., Keane N. M., Price P., French M. A. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J. Infect. Dis. 2002; 186: 1498–1502
   PubMed Web of Science ®Google Scholar
• Tsai S. L., Liaw Y. F., Chen M. H., Huang C. Y., Kuo G. C. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity. Hepatology 1997; 25(2)449–458
   PubMed Web of Science ®Google Scholar
• Wedemeyer H., He X. S., Nascimbeni M., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 2002; 169(6)3447–3458
   PubMedGoogle Scholar
• Chang K. M., Thimme R., Melpolder J. J., et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33(1)267–276
   Web of Science ®Google Scholar
• Lechner F., Gruener N. H., Urbani S., et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur. J. Immunol. 2000; 30(9)2479–2487
   Google Scholar
• Thimme R., Oldach D., Chang K. M., Steiger C., Ray S. C., Chisari F. V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001; 194(10)1395–1406
   PubMed Web of Science ®Google Scholar
• Diepolder H. M., Gerlach J. T., Zachoval R., et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 1997; 71(8)6011–6019
   Google Scholar
• Rosen H. R., Miner C., Sasaki A. W., et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: Correlation with clinical disease stages. Hepatology 2002; 35(1)190–198
   PubMed Web of Science ®Google Scholar
• Vertuani S., Bazzaro M., Gualandi G., et al. Effect of interferonalpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 2002; 32(1)144–154
   Google Scholar
• Wertheimer A. M., Miner C., Lewinsohn D. M., Sasaki A. W., Kaufman E., Rosen H. R. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37(3)577–589
   Google Scholar
• Bartosch B., Dubuisson J., Cosset F. L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003; 197(5)633–642
   PubMed Web of Science ®Google Scholar
• Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005; 11(7)791–796
   PubMed Web of Science ®Google Scholar
• Bartosch B., Bukh J., Meunier J. C., et al. In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. USA 2003; 100(24)14199–14204
   PubMed Web of Science ®Google Scholar
• Logvinoff C., Major M. E., Oldach D., et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2004; 101(27)10149–10154
   PubMed Web of Science ®Google Scholar
• Urbani S., Amadei B., Tola D., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 2006; 80(22)11398–11403
   PubMed Web of Science ®Google Scholar
• Lindenbach B. D., Evans M. J. A. J., Syder A J, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309(5734)623–626
   PubMed Web of Science ®Google Scholar
• ISVHLD. Abstracts of the 12th international symposium on viral hepatitis and liver disease. J. Clin. Virol. 2006; 36 S2(Suppl. 2)S4–S32
   Google Scholar
• Choo Q. L., Kuo G., Ralston R. R., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 1994; 91(4)1294–1298
   PubMed Web of Science ®Google Scholar
• Rosa D., Campagnoli S., Moretto C., et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc. Natl. Acad. Sci. USA 1996; 93(5)1759–1763
   PubMed Web of Science ®Google Scholar
• Nevens F., Roskams T., Van Vlierberghe H., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003; 38(5)1289–1296
   PubMed Web of Science ®Google Scholar
• Folgori A., Capone S., Ruggeri L., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 2006; 12(2)190–197
   PubMed Web of Science ®Google Scholar
• Weeratna R. D., Makinen S. R., McCluskie M. J., Davis H. L. TLR agonists as vaccine adjuvants: Comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005; 23(45)5263–5270
   PubMed Web of Science ®Google Scholar
• Horsmans Y., Berg T., Desager J. P., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42(3)724–731
   PubMed Web of Science ®Google Scholar